The term NPT2 Inhibitors in this context refers to a class of chemicals that can indirectly influence the activity or function of the sodium-dependent phosphate transport protein 2 (NPT2). NPT2 plays a crucial role in phosphate homeostasis, particularly in the kidneys, where it facilitates the reabsorption of phosphate from the renal tubules. The inhibitors listed do not target NPT2 directly but affect related physiological processes and pathways that can lead to changes in NPT2 activity or expression. These inhibitors work through diverse mechanisms, primarily focusing on modulating calcium and phosphate metabolism in the body. Compounds like Paricalcitol, Calcitriol, and Teriparatide are directly involved in regulating vitamin D metabolism or mimicking the action of parathyroid hormone. They can indirectly affect NPT2 function by altering the systemic balance of calcium and phosphate, which in turn influences renal phosphate handling. On the other hand, compounds such as Foscarnet, a pyrophosphate analog, and bisphosphonates like Alendronate, Pamidronate, Risedronate, and Zoledronic Acid, primarily affect bone mineralization and resorption. These processes are closely linked to phosphate metabolism, and thus, these compounds can indirectly impact the activity of NPT2 in the kidneys.
Additionally, agents like Sevelamer, a phosphate binder, reduce the intestinal absorption of phosphate, potentially altering the demand for renal phosphate reabsorption and hence influencing NPT2 activity. Similarly, Burosumab, an antibody targeting FGF23 (a hormone that regulates phosphate metabolism), can modulate systemic phosphate levels and indirectly affect NPT2. The indirect inhibition of NPT2 through these compounds is significant in the context of disorders related to phosphate imbalance, such as chronic kidney disease, hyperphosphatemia, and bone metabolism disorders. By influencing the systemic and cellular pathways that regulate phosphate homeostasis, these compounds can indirectly modulate the function of NPT2, thereby contributing to the maintenance of phosphate balance in the body.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Paricalcitol | 131918-61-1 | sc-477938 sc-477938A | 0.5 mg 1 mg | $450.00 $550.00 | 1 | |
A vitamin D analog, influencing calcium and phosphate homeostasis, potentially affecting NPT2 activity. | ||||||
Foscarnet sodium | 63585-09-1 | sc-205330 sc-205330A | 1 g 5 g | $190.00 $676.00 | ||
A pyrophosphate analog that can interfere with phosphate metabolism and may indirectly influence NPT2 activity. | ||||||
1α,25-Dihydroxyvitamin D3 | 32222-06-3 | sc-202877B sc-202877A sc-202877C sc-202877D sc-202877 | 50 µg 1 mg 5 mg 10 mg 100 µg | $220.00 $645.00 $1000.00 $1500.00 $440.00 | 32 | |
An active form of vitamin D, regulating calcium and phosphate metabolism, potentially influencing NPT2 function. | ||||||
Alendronate acid | 66376-36-1 | sc-337520 | 5 g | $135.00 | 2 | |
A bisphosphonate that affects bone mineralization and phosphate metabolism, potentially influencing NPT2 activity. | ||||||
Estramustine | 2998-57-4 | sc-353281 sc-353281A | 100 mg 1 g | $265.00 $743.00 | ||
A chemotherapy agent with potential effects on calcium and phosphate metabolism, indirectly affecting NPT2. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
A potent bisphosphonate affecting bone metabolism and phosphate balance, potentially influencing NPT2. | ||||||
Parathyroid hormone fragment (1-34) | 52232-67-4 | sc-487943 | 100 µg | $185.00 | ||
A recombinant form of parathyroid hormone, influencing calcium and phosphate metabolism, potentially affecting NPT2. | ||||||